American Diabetes Association
dc22-0835 supplements_revision_8_10.pdf (1.94 MB)

Biliopancreatic Limb Length as a Potential Key Factor in Superior Glycemic Outcomes After Roux-en-Y Gastric Bypass in Patients with Type 2 Diabetes: A Meta-analysis

Download (1.94 MB)
Version 2 2022-12-01, 21:04
Version 1 2022-12-01, 21:02
posted on 2022-12-01, 21:04 authored by Yeongkeun Kwon, Sungho Lee, Dohyang Kim, Ahmad ALRomi, Shin-Hoo Park, Min Chang Lee, Jong-Han Kim, Sungsoo Park


BACKGROUND: Optimal length of biliopancreatic (BP) and Roux limb in Roux-en-Y gastric bypass (RYGB) for improved glycemic control are not known.

PURPOSE: To investigate how the lengths of the BP and Roux limbs in RYGB differentially affect postoperative glycemic outcomes in patients with type 2 diabetes.

DATA SOURCES: Systematic literature search using the PubMed, EMBASE, and the Cochrane Library databases.

STUDY SELECTION: Studies that reported glycemic outcomes after RYGB and lengths of the BP and Roux limbs.

DATA EXTRACTION: Twenty-eight articles were included for data extraction. Glycemic outcomes after RYGB were assessed using two definitions: remission and improvement.

DATA SYNTHESIS:  We categorized the included studies into four groups according to the BP and Roux limb lengths. The type 2 diabetes remission/improvement rates (95% confidence interval [CI]) were as follows: long BP‒long Roux group, 0.80 (0.70‒0.90)/0.81 (0.73‒0.89); long BP‒short Roux group, 0.76 (0.66‒0.87)/0.82 (0.75–0.89); short BP‒long Roux group 0.57 (0.36‒0.78)/0.64 (0.53‒0.75); short BP‒short Roux group, 0.62 (0.43‒0.80)/0.53 (0.45‒0.61). Meta-regression analysis also showed that a longer BP limb resulted in higher postoperative type 2 diabetes remission and improvement rates, whereas a longer Roux limb did not. There was no significant difference or heterogeneity in baseline characteristics, including diabetes-related variables, among the four groups.

LIMITATIONS: Not all included studies were randomized controlled trials.

CONCLUSIONS: Longer BP limb length led to higher rates of type 2 diabetes remission and improvement by 1 year after RYGB than the longer Roux limb length.



Korea government x 9991007295, KMDF_PR_202012D13-02

Korea University

National Research Foundation of Korea 2020R1I1A1A01070106


Usage metrics

    Diabetes Care


    Ref. manager